Indivior Pharmaceuticals, Inc. (SPUN)
NASDAQ: SPUN · Real-Time Price · USD
36.28
+0.91 (2.57%)
At close: Nov 2, 2026
Indivior Pharmaceuticals Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Market Capitalization | 4,282 | 4,480 | 1,553 | 2,085 | 2,969 | 2,423 |
Market Cap Growth | - | 188.39% | -25.50% | -29.76% | 22.54% | 125.44% |
Enterprise Value | 4,478 | 4,391 | 1,519 | 1,640 | 2,327 | 1,706 |
Last Close Price | 36.28 | 27.84 | 9.64 | 11.85 | 16.88 | 13.38 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 10.21 | 21.33 | 221.91 | - | - | 11.82 |
Forward PE | 8.25 | 12.78 | 8.55 | 8.96 | 17.02 | 17.57 |
PS Ratio | 3.12 | 3.62 | 1.31 | 1.91 | 3.30 | 3.06 |
PB Ratio | - | -45.71 | -4.61 | -10.92 | 58.21 | 11.93 |
P/TBV Ratio | - | - | - | - | - | 20.02 |
P/FCF Ratio | 138.14 | - | 221.91 | - | - | 6.94 |
P/OCF Ratio | 44.61 | - | 43.15 | - | - | 6.86 |
PEG Ratio | - | 10.35 | 3.40 | 2.55 | 1.13 | 1.13 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.26 | 3.54 | 1.28 | 1.50 | 2.58 | 2.16 |
EV/EBITDA Ratio | 6.87 | 11.06 | 4.92 | 6.33 | 10.21 | 8.57 |
EV/EBIT Ratio | 6.94 | 11.35 | 5.13 | 6.64 | 10.82 | 9.12 |
EV/FCF Ratio | 144.46 | - | 217.05 | - | - | 4.89 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | -8.35 | -3.58 | -1.11 | -1.48 | 5.43 | 1.41 |
Debt / EBITDA Ratio | 0.75 | 0.86 | 1.17 | 1.05 | 1.21 | 1.39 |
Debt / FCF Ratio | 16.16 | - | 53.57 | - | - | 0.82 |
Net Debt / Equity Ratio | -3.27 | -1.59 | -0.16 | 0.67 | -12.08 | -4.02 |
Net Debt / EBITDA Ratio | 0.30 | 0.39 | 0.18 | -0.49 | -2.70 | -4.10 |
Net Debt / FCF Ratio | 6.32 | -1.68 | 7.86 | 0.41 | 68.44 | -2.34 |
Asset Turnover | 1.00 | 0.99 | 0.77 | 0.62 | 0.50 | 0.47 |
Inventory Turnover | 1.29 | 1.24 | 1.26 | 1.40 | 1.45 | 1.35 |
Quick Ratio | 0.45 | 0.49 | 0.66 | 0.52 | 1.10 | 1.64 |
Current Ratio | 0.62 | 0.71 | 0.90 | 0.98 | 1.24 | 1.80 |
Return on Equity (ROE) | - | - | - | - | -34.65% | 143.86% |
Return on Assets (ROA) | 29.34% | 19.22% | 12.03% | 8.75% | 7.46% | 6.95% |
Return on Invested Capital (ROIC) | 272.47% | 100.16% | 24.04% | 52.55% | - | - |
Return on Capital Employed (ROCE) | 2080.60% | 134.80% | 75.50% | 52.60% | 28.70% | 18.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 9.79% | 4.69% | 0.45% | -6.04% | -1.48% | 8.46% |
FCF Yield | 0.72% | -2.08% | 0.45% | -14.77% | -0.30% | 14.41% |
Buyback Yield / Dilution | 0.98% | 3.76% | 2.92% | 1.44% | 8.52% | -3.66% |
Total Shareholder Return | 0.98% | 3.76% | 2.92% | 1.44% | 8.52% | -3.66% |